News Focus
News Focus
icon url

tob999

09/28/15 12:20 PM

#9763 RE: grawsha #9762

Yup Zoptec phase III efficacy and safety results for endometrial cancer in early October.
icon url

chmcnfunds

09/28/15 12:25 PM

#9768 RE: grawsha #9762

Agree with that. There could be more news in addition to the interim analysis results which some don't consider a pps builder. Mid-November will be the time by which they need to deal with the Nasdaq continued listing issue. Presumably they will do a r/s to get the pps up to $2.50 as they have in the past and also deal with the $35M market cap minimum listing requirement.

AEZS